Cadonilimab: First Approval

Cadonilimab (开坦尼 ® ), a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumours, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, oesophageal squamous cell cancer, liver cancer and nasopharyngeal cancer. Cadon...

Full description

Saved in:
Bibliographic Details
Published in:Drugs (New York, N.Y.) N.Y.), 2022-08, Vol.82 (12), p.1333-1339
Main Author: Keam, Susan J.
Format: Article
Language:English
Subjects:
AdisInsight Report
Antibodies
Breastfeeding & lactation
Cancer therapies
Cell growth
Cervical cancer
Cervix
Chemotherapy
CTLA-4 protein
Cytokines
Cytotoxicity
Hepatocytes
Immunotherapy
Internal Medicine
Ligands
Liver cancer
Lung cancer
Lymphocytes
Medicine
Medicine & Public Health
Metastases
Metastasis
Patients
PD-1 protein
Pharmacokinetics
Pharmacology/Toxicology
Pharmacotherapy
Platinum
Solid tumors
Steroids
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cadonilimab (开坦尼 ® ), a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumours, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, oesophageal squamous cell cancer, liver cancer and nasopharyngeal cancer. Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or after platinum-based chemotherapy. This article summarizes the milestones in the development of cadonilimab leading to this first approval for the treatment of patients with r/mCC.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-022-01761-9